Ipilimumab-associated retinopathy

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 6, 2015, Pages 658-660

  Crews, Jonathan ^a   Agarwal, Aniruddha ^a   Jack, Loren ^a   Xu, Ding ^a,b   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOFLUORESCENCE; BLURRED VISION; BRAIN METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL SEROUS RETINOPATHY; CRANIOTOMY; EXCISION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIMODAL IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHOTOPHOBIA; PRIORITY JOURNAL; RETINA DETACHMENT; RETINOPATHY; SHOULDER DISEASE; SUBRETINAL FLUID; TREATMENT PLANNING; VISUAL ACUITY; VISUAL IMPAIRMENT; ADVERSE EFFECTS; CHEMICALLY INDUCED; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; RETINAL DETACHMENT; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; RETINAL DETACHMENT; SKIN NEOPLASMS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84937036900     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150610-10     Document Type: Article

References (17)

1. Berrocal A, Cabanas L, Espinosa E, et al. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations. Adv Ther.2014;31(9):945-960.
2. Pedersen M, Andersen R, Norgaard P, et al. Successful treatment with ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63(12):1341-1346.
3. Bhatia S, Thompson JA. Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Canc Netw. 2012;10(3):403-412.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
5. Schadendorf D, Hauschild A. Melanoma in 2013: Melanoma-the run of success continues. Nat Rev Clin Oncol. 2014;11(2):75-76.
6. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37(5):485-498.
7. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043-6053.
8. Liu CY, Francis JH, Brodie SE, et al. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina. 2014;34(7):1261-1280.
9. Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw. 2014;12(8):1077-1081.
10. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retina Cases Brief Rep. 2012;6(4):423-426.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
12. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011;29(3):489-498.
13. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950-5956.
14. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-164.
16. McCannel TA, Chmielowski B, Finn RS, et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014;132(8):1005-1009.
17. Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25(7):1437-1441.